| Bioactivity | SKLB-163 is an orally active inhibitor for Rho GDP-dissociation (RhoGDI). SKLB-163 inhibits highly expressed RhoGDI tumor cell proliferation and migration, and increases radiosensitivity of tumor cells. SKLB-163 induces cancer cell Apoptosis[1][2]. |
| Invitro | SKLB-163 (0-20 μM，48 小时) 抑制鼻咽癌 (NPC) 细胞的增殖和迁移，并使细胞对辐射敏感[1]。SKLB-163 (0-20 μM，48 h) 在 A375、SPC-A1、SW620、HeLa、PC-3 细胞中显示出细胞毒性作用[2]。SKLB-163 (0-2.5 μM，48 小时) 诱导 A375 细胞凋亡并抑制集落形成[2]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> SKLB-163 相关抗体: |
| In Vivo | SKLB-163 (25-100 mg/kg，灌胃，每天一次，持续 30 天) 抑制鼻咽癌小鼠模型中肿瘤生长和腹水形成，并抑制肝和肺转移[1]。SKLB-163 （50 mg/kg，每天一次。从 SKLB-163 给药第 6 天开始，每天一次 3 Gy 辐射，持续 3 天) 使 CNE-2 和 C666-1 皮下异种移植小鼠模型中的 NPC 肿瘤对辐射敏感[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1255099-06-9 |
| Formula | C18H16ClN3O2S2 |
| Molar Mass | 405.92 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. He J, et al. Antitumor and radiosensitizing effects of SKLB-163, a novel benzothiazole-2-thiol derivative, on nasopharyngeal carcinoma by affecting the RhoGDI/JNK-1 signaling pathway. Radiother Oncol. 2018 Oct;129(1):30-37. [2]. Peng X,et al. SKLB-163, a new benzothiazole-2-thiol derivative, exhibits potent anticancer activity by affecting RhoGDI/JNK-1 signaling pathway. Cell Death Dis. 2014 Mar 27;5(3):e1143. |
SKLB-163
CAS: 1255099-06-9 F: C18H16ClN3O2S2 W: 405.92
SKLB-163 is an orally active inhibitor for Rho GDP-dissociation (RhoGDI). SKLB-163 inhibits highly expressed RhoGDI tumo
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.